Purpose: Intensity-modulated proton therapy (IMPT) is known to be sensitive to patient setup and range uncertainty issues. Multiple robust optimization methods have been developed to mitigate the impact of these uncertainties. Here, we propose a new robust optimization method, which provides an alternative way of robust optimization in IMPT, and is clinically practical, which will enable users to control the balance between nominal plan quality and plan robustness in a user-defined fashion. Method: We calculated nine individual dose distributions which corresponded to one nominal and eight extreme scenarios caused by patient setup and proton beam's range uncertainties. For each voxel, the normalized dose interval (NDI) is defined as the full dose range variation divided by the maximum dose in all uncertainty scenarios (NDI = [max -min dose]/max dose), which was then used to calculate the normalized dose interval volume histogram (NDIVH) curves. The areas under the NDIVH curves were used to quantify plan robustness. A normalized dose interval volume constraint (NDIVC) applied to the target was incorporated to specify the desired robustness which was user-defined. Users could then explore the trade-off between nominal plan quality and plan robustness by adjusting the position of the NDIVCs on the NDIVH curves freely. We benchmarked our method using one lung, five head and neck (H&N), and three prostate cases by comparing our results to those derived using the voxel-wise worst-case robust optimization. Results: Using the benchmark cases, our new method achieved quality IMPT plans comparable to those derived from the voxel-wise worst-case robust optimization for both nominal plan quality and plan robustness in general; even more conformal and more homogeneous target dose distributions in some cases, if proper NDIVCs were applied. The AUC under NDIVH, as a precise quantitative index of plan robustness, was consistent with DVH bandwidths. Additionally, we demonstrated the feasibility of adjusting the position of NDIVCs in the NDIVH curves which allowed users to explore the trade-off between nominal plan quality and plan robustness. Conclusions: The NDIVH-based robust optimization method provided a novel and individualized way of robust optimization in IMPT, and enables users to adjust the balance between nominal plan quality and plan robustness in a user-defined fashion. This method is applicable for continued improvement and developing the next generation of IMPT planning algorithms in the future.
INTRODUCTION
Intensity-modulated proton therapy (IMPT) is an advanced form of particle beam-based technologies that delivers highly conformal tumoricidal dose to target volumes and with impressive sparing of adjacent healthy tissues compared to x ray or Rontgen-based conventional radiotherapies. The energies deposited are highly concentrated at or near the distal end of proton beams called the Bragg Peak. However, this very sharp gradient of dose distribution which is inherent to proton beams also makes proton therapy more sensitive to patient setup and range uncertainties, especially under intensely modulated and dose-painting techniques such as IMPT. Range uncertainties can arise from a number of sources including computed tomographic (CT) number uncertainty (the Hounsfield unit scale), tumor shrinkage, patient weight changes, respiratory and other physiologic changes, and uncertainty associated with the conversion of CT numbers to proton stopping powers. Appreciable degradation of the delivered dose distributions may also occur from setup uncertainties that are due to misalignment of beams and patient's position and/or related motions, which can generate both interfractional and also intrafractional errors.
There are a number of ways to address these uncertainties in the process of treatment planning. The traditional method used in photon therapy is to adopt additional margins to clinical target volume (CTV) to form planning target volume (PTV), which ensures adequate dose coverage to the CTV, a smaller volume. However, this method does not take into account the changes along the proton's beam track, tends to overestimate the effect of uncertainties, which results in irradiating more normal tissues potentially, or underestimate the effect of uncertainties which causes under-dosing the target; none of these would be ideal in robust IMPT planning.
As a result, various robustness quantification methods to assess plan robustness have been developed. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] For example, the dose volume histogram (DVH) band method has been widely adapted in Eclipse TM (Varian Medical Systems, Palo Alto, CA) and RayStation TM (RaySearch Laboratories, Stockholm, Sweden), 15, 16 and is well-received in proton therapy community. In a previous study, 13, 17 the concepts of the error bar and error-bar volume histograms are introduced to quantify the extent of plan robustness, and have been shown to be effective for robustness quantification. In this study, we introduced a novel concept of normalized dose interval (NDI) which was an extension of the error-bar concept. In this method, we did not calculate the worst-case doses, however, the normalized dose interval (NDI = [D max -D min ]/D max ) was used. Afterwards, the normalized dose interval volume histogram (NDIVH) was computed. The area under the NDIVH curve (AUC) was then used to quantify plan robustness as proposed in the previous studies. 1, 3, 13, 14, [18] [19] [20] More effective methods to account for uncertainty typically include robust optimization procedurally. They can be performed in different ways such as the probabilistic robust optimization method, 21 the objective-wise min-max robust optimization method, 22 or the voxel-wise worst-case robust optimization method. 11, 23, 24 For the voxel-wise worst-case robust optimization method, the uncertainties are represented by a number of scenarios considering setup and range uncertainties. For each voxel, multiple doses are calculated corresponding to uncertainty scenarios to form the worst-case dose distribution, which is in turn used in the optimization. Consequently, the resultant plan is expected to meet the clinical requirements under less extreme scenarios. Voxel-wise worstcase robust optimization had been shown to be effective in achieving robust IMPT plans. 1, 3, 11, [18] [19] [20] [23] [24] [25] However, the method cannot overcome the challenge that it does not balance between plan robustness and nominal plan quality in a user-defined way. The penalty weight of the plan robustness term in the objective function may be overshadowed in a mathematical context. However, the quantitative relationship between the penalty weight and the robustness of the resultant plan is not clear, and can vary based on various clinical scenarios; the importance of this in the IMPT practice is still to be determined. This unclear relationship will result in more "try and error" iterations at some situation in clinical practice where a certain amount of robustness is desired. This weakness is commonly shared with other robust optimization methods such as probabilistic robust optimization and objective-wise min-max robust optimization. 11, 18, 19, [21] [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] In the recent literatures, two methods to explore the tradeoff between nominal plan quality and robustness have been reported: (a) adjusting the weight of one plan robustnessrelated terms in the objective function, for example, by Pflugfelder et al. 23 ; and (b) using a multi-criteria optimization (MCO) framework, for example, by Chen et al. 26 . In the current study, we proposed a new robust optimization method based on the concept of normalized dose interval volume constraints (NDIVC). We controlled the plan robustness by modifying the shape of the NDIVH curves via NDIVC, thereby efficiently balancing plan quality and plan robustness. The proposed method in this framework is therefore novel, and differs from the reported methods as mentioned above. 23, 26 It is well-known that, when we use dose volume constraints (DVC) to control the nominal plan quality, we can adjust: (a) the weights of DVC-related terms; and/or (b) the DVC positions in the dose volume histogram (DVH) curves. The latter strategy is usually more effective and more clinically meaningful than the approach of adjusting the weight of the DVC terms in the objective function for controlling nominal plan quality. In the DVC method, the physical meaning of the DVC parameters, based on dose value and volume, are easily understood by the treatment planner and also the radiation oncologist 37 ; this enables controlling the plan quality in a user-friendly way. In this work, we did not only simply adjust the weights for the normalized dose interval (NDI) penalty terms, but also we actually adjusted the various positions of NDIVCs along the NDIVH curves. By assigning a smaller NDI value based on a NDIVC constraint point, we can generate a more robust plan but at the cost of plan quality as a trade-off. We found this approach more effective than the approach of adjusting the weight of the NDIVC terms in the objective function for controlling plan robustness. This method of controlling plan robustness has not been previously explored nor reported by any other groups before.
MATERIALS AND METHODS

2.A. Voxel-wise worst-case robust optimization
In the voxel-wise worst-case robust optimization, we considered nine typical extreme uncertainty scenarios: for setup uncertainties, the isocenter of the patient's planning CT was shifted by a certain distance in six directions in the Cartesian coordinates, and for the range uncertainties, the relative stopping power ratio was changed by AE3.5% to model minimum vs maximum range uncertainty scenarios, and also included one nominal scenario. The "worst-case scenario" dose per voxel was defined as the lowest dose per voxel in the CTV among all possible uncertainty scenarios, while the highest dose per voxel outside the CTV was also similarly defined among the same uncertainty scenarios. 8 The "worst-dose" distribution was then used in the optimization according to Ref. [11, 24] 
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whereas F WC was the value of the objective function in the WC (voxel-wise worst-case robust optimization) method. 
2.B. Normalized dose interval volume histogram (NDIVH) and area under the NDIVH curve (AUC) for plan robustness
We calculated the NDI index at each voxel's position, according to the following formula, NDI = (D max -D min )/ D max , thus forming a three-dimensional (3D) representation based on NDI. Then, we adopted the framework of DVH and performed similar statistical analyses and transformation to form the NDIVH which was analogous to the error-bar volume histograms (EVHs) as proposed by Albertini et al. 17 , with the vertical axis indicating the normalized volume of a particular structure, and the horizontal axis indicated the normalized dose interval (i.e., dose variation due to uncertainties) within a particular structure. A typical example of NDIVH is shown (Fig. 1 ). Similar to a data point on a DVH curve, the purple cross of the solid line in Fig. 1 indicated that 60% of the selected structure (target in this case) has a NDI (e.g., dose variation due to uncertainties) of at least 0.02. This method allowed for a straightforward and quantitative illustration how the dose variation was distributed within the selected structure. With our new method, this dashed line (voxel-based WC method) could then be pulled down into the solid curve (NDIVC-based optimization) as shown in Fig. 1 . In this case, 60% of the selected structure now had the NDI at least 0.004, which indicated that the plan became more robust. Furthermore, the area under the NDIVH curve (AUC) 1, 3, 13, 14, [18] [19] [20] allowed for calculation of a numerical index summarizing plan robustness in a manner analogous to the equivalent uniform dose summarized in an DVH; a smaller AUC value indicated better plan robustness. Those numerical values can be used in a statistical study such as Student's t test to compare plan robustness between two competing treatment planning methods.
The DVH band method 11, 12 was also used with the band width at D 95% of CTV to indicate the plan robustness. This method was used to crosscheck the validity of the NDIVH to quantify plan robustness.
2.C. Normalized dose interval volume histogram (NDIVH)-based robust optimization
It is well known that DVCs as commonly used in the radiation therapy treatment planning are effective in controlling the shape of the DVH curves and, therefore, effectively improve the plan quality of the final radiotherapy plans. Here, we adopted a similar concept by employing the NDIVC to control the shape of the DIVH curves, and with the goal of effectively improving plan robustness of the resultant radiotherapy plans.
An additional term related to aforementioned NDIVC [the underscored term in Eq. (2)] for the target was added to the objective function used in the worst-case robust optimization 
In the above formula, the first term represented the nominal plan quality of the target; the second term represented the plan robustness of the target, and the third term represented the relative values of normal tissue protection. The gradient of the above objective function can then be formulated as follows:
In Eqs. (2) and (3) It should be noted that the objective function used in this method was not convex just as the conventional voxel-wise worst-case robust optimization method, 1, 3, 11, [18] [19] [20] [22] [23] [24] [39] [40] [41] [42] and we did not try to calculate the derivatives of the Heaviside and the maximum/minimum functions, which are shown above in the objective function. The DVCs and the NDIVC were implemented as "soft constraints" in the objective function following the method proposed in Wu and Mohan. 38 Usually a trial-and-error process was needed to achieve a clinically acceptable plan. In some difficult cases, one constraint may not be met unless other objectives were sacrificed.
Here, we give more details about how we could implement NDIVCs in the objective function as "soft constraints" (Fig. 2) . 38 In Fig. 2 , the NDIVCs to limit the hot spots in the NDIVH curves could be specified as:
, that is, the volume receiving NDI greater than NDI 1 should still be less than V 1 : Following the same logic proposed by Wu and Mohan, 38 another NDI value NDI 2 could then be derived so that in the current NDIVH, V NDI 2 ð Þ¼V 1 . Only voxels with NDI values between NDI 1 and NDI 2 were penalized in the second term of the objective function above. The ellipsis of the second term showed that additional NDIVC for the target (also normal tissues if necessary) could be specified to have more complete control of NDIVH curves' shape. Similar concepts could also be applied to the NDIVCs and limited the cold spots in the targets' NDIVH curves which could be useful in certain scenarios.
We used a popular optimization algorithm, limited-memory Broyden-Fletcher-Goldfarb-Shanno (L-BFGS), 43 to assist in our treatment plan optimization. The algorithm was integrated in a well-benchmarked open source C++ optimizer package, OPT++ (Sandia National Laboratories, Albuquerque, NM). 44 It is worth noting that, as this complex problem was probably not quadratic or even convex, therefore, using the L-BFGS algorithm did not guarantee convergence to the global minimum. The "trial-and-error" process was incorporated for the patients included in this work to make sure that we could achieve a clinically acceptable plan that met all clinical requirements. For each iteration during the optimization process, the uncertainty scenario to be chosen per voxel was based on which of those scenarios would lead to the worst-case dose per voxel. We then calculated the objective function value and the corresponding gradient of 
Medical Physics, 46 (1), January 2019 that objective function based on the chosen uncertainty scenario per voxel, and used L-BFGS to derive the updated optimization solution. The same optimization algorithm L-BFGS had been successfully used in the voxel-wise worst-case robust optimization method, which utilized a similar nonconvex treatment planning model. 1, 3, 11, 18, 20, 24, 42 The most recent version of the commercial treatment planning system Eclipse ™ (Varian Medical Systems, Pal Alto, CA) has adopted the L-BFGS optimization algorithm in their new nonlinear universal proton optimizer (NUPO), which is clinically used at our institution and also other radiation clinics globally.
2.D. Patient data and evaluation
In this study, we retrospectively generated IMPT plans for eight clinical cases including one lung, two prostate, and five head and neck (H&N) cancer cases (Table I) . Two plans were generated for each patient with identical dosimetric goals and physics characteristics of spots: one using the voxel-wise worst-case robust optimization and the other one with our new NDIVH-based robust optimization as described above. We then compared the nominal plan quality and robustness between the two methods. The initial spot arrangements were the same for both methods, including position, intensity, energy, and spacing for fair comparison. Plans were normalized to have the same mean dose for the targets.
The following dosimetric parameters were used to compare plan quality and robustness: doses that cover 95% of the ROI (D 95% ); 25% of the ROI (D 25% ); 5% of the ROI (D 5% ); 1% of the ROI (D 1% ); and the mean dose.
RESULTS
3.A. Worst-case vs NDIVH-based robust optimization methods
3.A.1. Comparison summary
The statistics of the comparison of the DVH indices between the two methods applied to the eight clinical cases are summarized in Fig. 3 . In general, for the nominal scenario, the new NDIVC method achieved better or equal target coverages (higher in CTV D 95% , for seven out of the eight cases) compared to the WC method. The new NDIVC method also achieved better target homogeneity (CTV D 5% -D 95% ) in nominal scenario for seven out of the eight cases. The new NDIVC method achieved better or equal level of protection (lower in the corresponding DVH indices) in 7 out of 16 critical organs at-risk demonstrated. In terms of DVH band widths, the new NDIVC method achieved smaller (i.e., better) or equal robustness band width in 17 out of 32 cases. In general, we observed that the new NDIVC method could achieve IMPT plans with comparable nominal plan quality and plan robustness when proper NDIVC functions were used. Figure 4 shows the NDIVH comparisons for the prostate P1, the H&N H1, and lung L cases. The NDIVH AUCs of the NDIVC vs the WC methods were 0.0073 vs 0.0264, 0.0112 vs 0.0127, and 0.0153 vs 0.0166, respectively (smaller numbers were better). For the prostate and the H&N cases, the NDIVHs of the NDIVC method (in red) were always consistently below those of the WC method (in blue). For the lung case, the NDIVH curve by the NDIVC method did cross the WC curve at lower volumes (lower in the low NDI region, and higher in the high NDI region but only by a small amount).
3.A.2. Plan robustness comparison using NDIVH
3.A.3. Plan robustness comparison using the DVH Band methods
To compare plan robustness and nominal plan quality for the three cases using both methods, the DVH band methods 11, 12, 24 for the targets and selected critical organs are shown in Fig. 5 . In the left column, we show that the new method achieves better plan quality (fewer cold and hot spots) and robustness (thinner DVH band) for the prostate's target (P1), while it sacrificed a small amount of organ protection (bladder and femoral head). In the DVH band was consistent with the NDIVH AUC method in all three cases. Figure 6 shows the transverse dose distributions at two selected CT slices for the prostate (P1) case. They were compared for the cold and hot spots in the plans derived from the worst-case (left) and the NDIVH-based (right) robust optimizations, respectively. We demonstrated that the NDIVHbased robust optimization method (right) achieved a more conformal dose distribution and also better homogeneity within the target. These results were consistent with previous ones as shown in Figs. 3 and 5. Table II shows the comparison of the optimization times spent between the two methods, which were based on the L-BFGS optimizer using 48 CPU's at our in-house highperformance computing cluster. In general, the optimization time for the two methods was comparable, and appeared to favor NDIVC especially for the two most complicated cases (H3 and L). Overall, there was no significant difference for the total MUs of these plans between the two methods.
3.A.4. Comparison of Target coverage and homogeneity using transverse dose distributions
3.A.5. Performance comparison
3.B. Explicit control of plan robustness using the NDIVH-based robust optimization
Adjusting the NDIVC parameters can result in plans with different levels of plan robustness. Figure 7 shows the comparisons of the plan robustness and plan quality in IMPT planning for the prostate (P1) case, as generated by the NDIVH-based robust optimization under various NDIVC parameters. The NDVIC was applied to the target only. Figure 7 (left column) compares the plan quality by showing the DVHs of targets and normal tissues in the nominal scenario. 
DISCUSSIONS
In this study, we proposed a new quantitative index of plan robustness, namely area under the NDIVH curve, as a new robust optimization method based on NDIVC which aims directly to control plan robustness in a user-defined and quantitative way according to patient-specific treatment priorities. It is not the ultimate purpose of this work to show that our new method is superior to any other existing methods, but rather we aim to provide an alternative way of robust optimization in IMPT and a clinically practical way to enable users for controlling the balance between nominal plan quality and plan robustness in a user-friendly fashion. We have also generated multiple examples and comparison to demonstrate the pragmatic nature of this approach, and the potential benefits associated with this new method.
Currently, there are multiple ways to evaluate plan robustness. As discussed in Liu et al. 14 , the conventional DVH band width 11, 12, 24 and the worst-case analyses [8] [9] [10] have distinguished themselves for common practice use. However, the conclusions drawn may be dependent on the DVH parameters that are chosen for analyses. For example, when comparing two plans in terms of plan robustness, the comparison between two DVH band widths at target's D 5% and D 95% could yield conflicting information at times, for example, the top left panel of Fig. 5 (CTV plan robustness, P1 case). Similar phenomenon can be observed in the worst-case analysis method. Additionally, these methods are difficult to apply and summarize statistically especially when multiple cases are indicated. As a result, in routine clinical practice, a single, overall numerical value is preferred for representing plan robustness.
Analogous to the concepts of error bars and error barbased volume histograms to represent plan robustness, 13, 17 we proposed the use of NDI index and area under the NDIVH curve in this work. Across a number of clinical scenarios, we have shown that the NDIVH-based and DVH bandwidth methods were qualitatively consistent as an assessment tool for plan robustness. Numerical values (i.e., area under the NDIVH curve) can be derived from the NDIVH method and used to statistically evaluate and compare plan robustness across different scenarios.
We decided to use normalization in the plan robustness quantification and NDIVH-based robust optimization because the magnitude of dose variation differences can be compared across different nominal doses for plan robustness and accounted for voxel uncertainties. We also found that, after normalization, it is more effective and direct for users to shape the NDIVH curves (thus controlling plan robustness) in NDIVC-based robust optimization according to the user's preference and also needs for clinical judgment at that time (individualized dosimetric planning for IMPT).
With our newly proposed NDIVC-based robust optimization method, one can improve nominal plan quality by sacrificing plan robustness in the face of uncertainties, or vice versa which is often dependent on the individual clinical scenario. The balance between nominal plan quality and plan robustness is highly dependent on which types of NDIVC are used in the optimization steps, and ultimately related to the patient and tumor-specific treatment priorities. Should a more robust plan be desired, we make more rigorous NDIVC values to achieve so; the contrary is also true (i.e., loosely applying NDVIC results in a less robust plan, but better plan quality).
The optimization times spent between the two methods was comparable over a wide range of clinical scenarios. Sometimes, the NDIVH curves of the two plans may intersect with each other. If this occurs, it will be up to the treating physician and physicist to choose the appropriate plan in a patient-specific manner, especially when the competing plans have similar NDIVH AUC values. The methods proposed in this work for exploring the trade-off between nominal plan quality and plan robustness differ significantly compared to previous methods. Chen et al. 26 developed a MCO framework to include plan robustness into IMPT treatment planning which allows users to simultaneously explore the trade-off between nominal plan quality and plan robustness. Such a method is flexible for users to explore the trade-off between plan robustness and plan quality in a systematic manner; however, their method was based on an MCO framework which required a database of precomputed anchor plans to approximate the Pareto surface. Compared to our single-step optimization method, numerous optimizations would have been needed to generate such database for MCO. The extensive computation requirements would be a significant obstacle for this to be implemented routinely in the clinic. As far as the authors know, no clinic with commercial treatment planning system has implemented this robust MCO optimization algorithm for IMPT.
As IMPT has a much larger number of optimization variables than intensity-modulated radiation therapy (IMRT) due to the additional dimension of particle energies, usually much longer computation and optimization times are required. In addition, the implementation of the MCO method is based on the linear projection solver, while the currently proposed NDIVC method is based on the conventional quadratic programming which is easier to integrate into the current commercial treatment planning systems, such as the popular Eclipse ™ software (Varian Medical Systems, Palo Alto, CA). On the other hand, in their voxel-based worst-case robust optimization method, Pflugfelder et al. 23 used a penalty term to control the relative importance of the worst-case dose distribution related to objective function term to the nominal dose distribution-related objective function term, thereby resulting in a trade-off between nominal plan quality and plan robustness. While it is a nice and relatively straightforward way to control the plan robustness in the IMPT treatment planning, unfortunately, users have relatively less control of the plan robustness before the optimization steps as compared to our new method. An even more detailed comparison between these two methods is warranted, and will be included in a future study.
A conditional value at risk chance constraints robust optimization method based on linear programming has been also proposed recently for improving plan robustness. 45 However, it can constraint only the tail mean dose value, and the slow computing speed makes it impractical for routine clinic use (at least for the time being). In addition, the use of linear programming is difficult to be integrated in certain commercial treatment planning systems such as Varian Eclipse The limitation of this study includes a small number of clinical cases considered. A larger patient population in different disease sites is warranted to generalize the conclusion, and additional studies are needed to evaluate if the currently proposed method is more effective over the traditional worst-case robust optimization method; a wider range of patients' anatomy and cases should be considered in the future.
CONCLUSIONS
The NDIVH-based robust optimization method provided a novel and individualized way of robust optimization in IMPT, and enables users to adjust the balance between nominal plan quality and plan robustness in a user-defined fashion. It is convenient for daily clinical use. This method is applicable for continued improvement and developing the next generation of IMPT planning algorithms in the future. 
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APPENDIX A DERIVATION OF THE GRADIENT OF THE NDI-RELATED TERM IN THE OBJECTIVE FUNCTION THE GRADIENT COMPUTATION
Here, we present the details how we derived the gradient formula [the underlined term of Eq. (3)]. We appreciate the referee for pointing this out, since the gradient formula being relatively simple is partly the reason why we believe our method can be efficient.
For simplification, we will only focus on the derivation of the gradient of the NDI-related term [the underlined term of Eq. (3)]. The derivation of the gradient of the other two terms is otherwise self-explanatory.
HEAVISIDE FUNCTIONS
As the referee pointed out, we used the Heaviside function H(NDI 2 -NDI i )H(NDI i -NDI 1 ) in Eq. (2) only for penalizing the voxels in target (i 2 CTV), which had the value of NDI i between NDI 1 and NDI 2 . We termed the volume composed of all the qualified voxels as the CTV_constraint. This new volume would be formed during each optimization iteration before calculating the value of the objective function and its gradient.
In this way, the following equation [the underlined term in Eq. (2)]:
